A clinical case of the effectiveness of chemo-targeted therapy in the first line of treatment for recurrent squamous cell carcinoma of the larynx


DOI: https://dx.doi.org/10.18565/pharmateca.2025.6.227-232

https://dx.doi.org/10.18565/pharmateca.2025.6.227-232

1) N.I. Pirogov Russian National Research Medical University, Moscow, Russia; 2) A.Tsyb Medical Radiology Research Center – Branch of the National Medical Research Radiological Center, Obninsk, Russia; 3) Moscow City Hospital named after S.S. Yudin, Moscow, Russia; 4) I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Background: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer, with laryngeal cancer accounting for only 0.6%. According to GLOBOCAN estimates (2022), approximately 890,000 new cases of HNSCC are registered worldwide each year, with mortality estimated at 450,000. In Russia in 2023, laryngeal cancer accounted for 2% of all malignant neoplasms among the male population. Despite the treatment, more than 50% of patients experience a relapse of the disease in the first 3 years. Modern methods of treating metastatic or recurrent HNSCC include both standard cytostatics and modern classes of antitumor drugs (targeted and immunotherapy).
Description of a clinical case: This article presents a clinical case of a long-term response to combined chemo-targeted (paclitaxel, carboplatin, cetuximab) therapy in a patient with recurrent squamous cell carcinoma of the larynx.
Conclusion: Combination chemo-targeted therapy (paclitaxel, carboplatin, cetuximab) as first-line treatment for recurrent/metastatic HNSCC demonstrates satisfactory tolerability with comparable oncological outcomes, especially in older patients and/or with significant comorbidities.
Keywords: squamous cell carcinoma of the larynx, recurrent laryngeal cancer, laryngeal cancer, cetuximab, targeted therapy
Read entire article

About the Autors

Ekaterina A. Novgorodova, Student, Faculty of General Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; ORCID: https://orcid.org/0009-0004-3111-7663
Pavel V. Golubev, Cand. Sci. (Med.), Oncologist, Department of Antitumor Drug Therapy, A.Tsyb Medical Radiology Research Center – Branch of the National Medical Research Radiological Center, Obninsk, Russia; ORCID: https://orcid.org/0000-0003-3532-6476 (Corresponding author)
Evgenia S. Kuzmina, Cand. Sci. (Med.), Head of Chemotherapy Department No. 2, Oncology Center No. 1, Moscow City Hospital named after
S.S. Yudin, Moscow, Russia; ORCID: https://orcid.org/0009-0007-2856-5176
Dmitry S. Pikulin, Oncologist, Day Hospital for Antitumor Drug Therapy No. 2, Oncology Center No. 1, Moscow City Hospital named after S.S. Yudin, Moscow, Russia; ORCID: https://orcid.org/0009-0000-1037-9729
Vladislav M. Kuzmin, Student, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ORCID: https://orcid.org/0009-0000-9658-3586
V.N. Galkin, Dr. Sci. (Med.), Professor, Chief Physician, Moscow City Hospital named after S.S. Yudin, Moscow, Russia; ORCID: https://orcid.org/0000-0002-6619-6179


Similar Articles

Back to Content

Бионика Медиа